{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.0","upperLimit":"218.0","value":"85.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG001","lowerLimit":"63.0","upperLimit":"NA","value":"105.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG002","lowerLimit":"129.0","upperLimit":"NA","value":"235.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG003","lowerLimit":"51.0","upperLimit":"NA","value":"168.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG004","lowerLimit":"52.0","upperLimit":"NA","value":"118.0"},{"comment":"The median and the upper limit of the confidence interval were not estimable because too few participants had disease progression or died.","groupId":"OG005","lowerLimit":"20.0","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"description":"According to mRECIST 1.1, PFS was defined as the length of time between the Baseline visit (Day 1) and the earlier of the participant's death or the first confirmed assessment of PD, as determined by investigator assessment of objective radiographic disease assessments. The response of target lesions was evaluated from the percentage change in the sum of the diameters of the viable portions (portions enhanced during the arterial phase).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with programmed cell death protein/programmed cell death ligand 1 (PD-1/PD-L1) relapsed melanoma (RM) received INCAGN01876 300 mg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV Q6W.","id":"OG000","title":"Phase 2 Group C2 PD-1/PD-L1 RM: INCAGN01876 300 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with gastric cancer (GC) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG001","title":"Phase 2 Group F GC: INCAGN01876 300 mg + Nivolumab 240 mg"},{"description":"Participants with squamous cell carcinoma of the head and neck (SCCHN) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG002","title":"Phase 2 Group F SCCHN INCAGN01876 300 mg + Nivolumab 240 mg"},{"description":"Participants with cervical cancer (CC) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG003","title":"Phase 2 Group F CC: INCAGN01876 300 mg + Nivolumab 240 mg"},{"description":"Participants with PD-1/PD-L1 relapsed melanoma received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG004","title":"Phase 2 Group F PD-1/PD-L1 RM: INCAGN01876 300 mg + Nivolumab 240 mg"},{"description":"Participants with gastric cancer, squamous cell carcinoma of the head and neck, cervical cancer, or PD-1/PD-L1 relapsed melanoma who had tumor lesions that were amenable to percutaneous biopsy received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG005","title":"Phase 2 Group F Biopsy: INCAGN01876 300 mg + Nivolumab 240 mg"}],"paramType":"MEDIAN","populationDescription":"Phase 2 FAS. Median survival time was estimated using the Kaplan-Meier method. The confidence interval for median survival time was calculated using the method of Brookmeyer and Crowley.","reportingStatus":"POSTED","timeFrame":"up to approximately 44.7 months","title":"Phase 2: PFS Per mRECIST v1.1","type":"SECONDARY","unitOfMeasure":"Days"}